Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mice with humanized FXR ligand-binding domain display distinct metabolic responses upon pharmacological FXR stimulation.

Journal of lipid research·2026
Same author

Plasma Citrate Levels Are Inversely Associated with Estimated Muscle Mass and Strength in Liver Transplant Recipients.

International journal of molecular sciences·2026
Same author

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.

Cardiovascular diabetology·2026
Same author

Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies.

The lancet. Diabetes & endocrinology·2026
Same author

Bile Acid Detergency as Determinant of Liver Pathology in a Humanized Mouse Model of Progressive Familial Intrahepatic Cholestasis Type 3.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Farnesoid x Receptor Deficiency Promotes Hepatocytic Injury in Cyp2c70-Deficient Mice With a Human-Like Bile Acid Composition.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same journal

Pacemaker Status and 5-Year Mortality After TAVI: A Sex-Specific Analysis.

European journal of clinical investigation·2026
Same journal

Causal Effects of Time-Varying Treatments: The G-Formula.

European journal of clinical investigation·2026
Same journal

Improving Scientific Research: Renegotiated Principles of Science, Proposals, Failures, and Successes.

European journal of clinical investigation·2026
Same journal

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.

European journal of clinical investigation·2026
Same journal

Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.

European journal of clinical investigation·2026
Same journal

Circulating Human Epididymis Protein 4 Predicts 10-Year Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease.

European journal of clinical investigation·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.

Paul J W H Kappelle1, Jan Freark de Boer, Frank G Perton

  • 1Department of Endocrinology, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

European Journal of Clinical Investigation
|September 30, 2011
PubMed
Summary
This summary is machine-generated.

High-density lipoprotein (HDL) antioxidative capacity is reduced in type 2 diabetes due to lower HDL cholesterol. Increased lecithin:cholesterol acyltransferase (LCAT) activity and lower paraoxonase-1 (PON-1) activity contribute to this impairment.

Related Experiment Videos

Last Updated: May 29, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Area of Science:

  • Cardiovascular Research
  • Metabolic Disorders
  • Lipid Metabolism

Background:

  • Type 2 diabetes mellitus (T2DM) elevates atherosclerotic cardiovascular disease (ASCVD) risk.
  • High-density lipoprotein (HDL) possesses atheroprotective antioxidative properties.
  • The impact of T2DM on HDL antioxidative functionality requires investigation.

Purpose of the Study:

  • To determine if HDL antioxidative functionality is altered in T2DM.
  • To identify factors influencing HDL antioxidative parameters in T2DM.

Main Methods:

  • Cross-sectional study of 74 T2DM patients and 75 controls.
  • Measurement of HDL antioxidative capacity and HDL antioxidation index.
  • Assessed lecithin:cholesterol acyltransferase (LCAT) and paraoxonase-1 (PON-1) activities.

Main Results:

  • HDL antioxidation index was lower in T2DM patients due to reduced HDL cholesterol.
  • LCAT activity was higher, and PON-1 activity was lower in T2DM.
  • High LCAT activity was independently associated with decreased HDL antioxidative capacity and index.

Conclusions:

  • HDL antioxidative functionality is impaired in T2DM, primarily due to lower HDL cholesterol.
  • Hyperglycemia, elevated LCAT activity, and reduced PON-1 activity contribute to impaired HDL function.
  • These findings highlight potential therapeutic targets for mitigating cardiovascular risk in T2DM.